MBRX Profile
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, specializes in developing innovative drug candidates aimed at treating highly resistant tumors and viral infections. The company is advancing its lead drug candidate, Annamycin, which is currently undergoing Phase 1/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers that have metastasized to the lungs. Annamycin is a novel anthracycline with potential to address resistance issues associated with traditional AML therapies.
Moleculin's flagship immune and transcription modulator, WP1066, is in Phase I clinical trials targeting brain tumors, including pediatric brain tumors, as well as pancreatic cancer and other malignancies. WP1066 is designed to inhibit key signaling pathways involved in tumor progression, offering a promising approach for cancers that are difficult to treat with existing therapies. Additionally, the company is developing WP1220, an analog of WP1066 intended for the topical treatment of cutaneous T-cell lymphoma, and WP1122, which is being explored for its potential to treat glioblastoma multiforme and COVID-19.
The company's research and development efforts are supported through various partnerships and collaboration agreements with prominent institutions and organizations. Notable collaborations include agreements with MD Anderson Cancer Center, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. These partnerships enhance Moleculin's ability to advance its drug candidates through clinical development and potentially bring new therapies to market.
Incorporated in 2015 and headquartered in Houston, Texas, Moleculin Biotech, Inc. is dedicated to addressing unmet medical needs through its innovative therapeutic approaches. The company's focus on developing treatments for resistant cancers and viral infections positions it as a key player in the pharmaceutical industry, committed to advancing the science of oncology and infectious disease. As clinical trials progress and new collaborations are established, Moleculin aims to make significant contributions to the treatment landscape for complex and challenging diseases.
|
